List view / Grid view
“Our collaboration with Sangamo is expected to help us expand…
9 January 2014 | By Biogen Idec
“Our collaboration with Sangamo is expected to help us expand our capabilities to develop treatments for people with serious, inherited hematologic conditions..."
U.S. and EU regulatory authorities have accepted marketing applications...
19 July 2013 | By Biogen Idec
U.S. and EU regulatory authorities have accepted marketing applications...
EMA submission planned in the coming weeks...
21 May 2013 | By Biogen Idec
EMA submission planned in the coming weeks...
EMPOWER trial fails to demonstrate efficacy in primary and key…
3 January 2013 | By Biogen Idec
EMPOWER trial fails to demonstrate efficacy in primary and key secondary endpoints...
Two new dosing innovations designed to help patients receiving once-a-week…
14 May 2012 | By Biogen Idec
Two new dosing innovations designed to help patients receiving once-a-week AVONEX...
Dosing enhancements may improve treatment experience for patients receiving AVONEX®…
28 February 2012 | By
Dosing enhancements may improve treatment experience for patients receiving AVONEX® (interferon beta-1a) for MS...
EMA submission anticipated within the coming days...
28 February 2012 | By Biogen Idec
EMA submission anticipated within the coming days...
Biogen Idec and Stromedix, Inc. announced that they have entered…
14 February 2012 | By Biogen Idec
Biogen Idec and Stromedix, Inc. announced that they have entered into a definitive agreement under which Biogen Idec will acquire Stromedix Inc...
Results from a study that suggest that inhibiting death receptor-6…
3 July 2011 | By Biogen Idec
Results from a study that suggest that inhibiting death receptor-6 (DR6) function may represent a novel approach...
Biogen Idec announced that the European Commission has granted approval…
7 June 2011 | By Biogen Idec
Biogen Idec announced that the European Commission has granted approval to AVONEX PEN...
